Latest News and Events
Filter by
Selections
March 24, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Read MoreMarch 15, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Read MoreFebruary 24, 2022
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
Read MoreFebruary 18, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreJanuary 24, 2022